Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE 1: Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis
2020-000955-11Phase 3Active
- Sponsor
- Sun Pharma
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Tildrakizumab with Placebo (2 arms). Primary endpoint: ACR20 response rate at Week 24. Started Oct 2020; status: active.
02
Drugs
tildrakizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2020-000955-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000955-11.